



FACT SHEET

Michelle Claypool
Public Relations
+1-763-526-9452

Fact Sheet SynchroMed™II Intrathecal Drug Delivery System (Medtronic pain pump) for Chronic Pain

CHRONIC PAIN

Chronic pain, which lasts more than three to six months, is a disabling condition that adversely affects wellbeing and can interfere with working, sleeping, and participating in physical activities, ultimately affecting quality of life. At least 100 million American adults – more than those affected by heart disease, cancer, and diabetes combined – are affected by chronic pain.¹ It is estimated that the cost to treat chronic pain in the U.S., as well as related lost productivity, is as high as \$635 billion annually.²

CHRONIC PAIN TREATMENT OPTIONS

There is a myriad of treatment options available for those suffering from chronic pain and underlying conditions that can cause chronic pain. Patients should talk to their doctor about the right treatment for them. Treatments may include:

- **Behavior modification:** exercise, relaxation, training, support groups
- **Rehabilitation:** physical therapy, chiropractic care, massage, acupuncture
- **Oral medications:** mild pain relievers such as ibuprofen, opiates such as morphine, and other types of drug such as anti-depressants
- **Radio Frequency (RF) Ablation:** heat generated by radio waves to target specific nerves and temporarily turn off their ability to send pain signals
- **Corrective surgery:** addressing the condition causing pain through back surgeries such as disc decompression, microdiscectomy, laminectomy, spinal fusion or foraminotomy
- **Implantable medical devices:** neurostimulation that blocks pain signals as they travel through the nervous system to the brain where pain is perceived or targeted drug delivery (TDD) that releases prescribed amounts of pain medication directly into the intrathecal space, near pain receptors in the spine instead of the circulatory system.

TARGETED DRUG DELIVERY (TDD)

Targeted Drug Delivery (TDD) is a safe, proven, and effective way to manage chronic pain, with fewer side effects and lower doses than oral medication.^{3,4}

Four key products work together to provide precise pain relief:

- **SynchroMed™ II Pump (Medtronic Pain Pump):** A programmable implantable pump that accurately delivers medication per the dosing instructions provided by a physician.
- **Ascenda™ Catheter:** A thin, flexible tube that connects to the pump and delivers medication directly into the fluid surrounding the spinal cord.
- **Clinician Programmer:** A physician uses the tablet to tailor the therapy to best meet patients needs.
- **myPTM™ Personal Therapy Manager:** This handheld device prescribed by a physician at time of implant helps patients manage unpredictable pain. The myPTM allows patients to receive an extra dose of pain medication when needed, within physician -prescribed limits.

TDD is not for everyone. In addition to surgical risks, such as infection and drug-related adverse events, pump or catheter problems can occur and may be life threatening, result in spinal cord injury, or require corrective surgery. To understand the benefits and risks of this therapy, please talk to your doctor. For additional safety information, please refer to the important safety information at [Medtronic.com/SynchroMedSafety](https://www.Medtronic.com/SynchroMedSafety).

SYNCHROMED™ II INTRATHECAL DRUG DELIVERY SYSTEM (MEDTRONIC PAIN PUMP)

The SynchroMed™ II Intrathecal Drug Delivery system, also known as the Medtronic pain pump, delivers medication directly to the fluid around the spinal cord to treat chronic intractable pain. It is an alternative to oral opioids for patients and provides effective pain relief at a fraction of the oral dose with fewer side effects and may help reduce or eliminate the use of oral opioids.³⁻⁹

A programmable implantable pump is connected to a thin, flexible tube that releases the pain medication directly into the fluid surrounding the spinal cord, an area called the intrathecal space. Because TDD releases small amounts of medication, pain can be controlled with a fraction of the oral medication dose.⁴ Most people experience fewer or more tolerable side effects versus oral dosing.⁴ TDD may provide relief for appropriate patients when other treatments—like oral medications or injections—have not.

The Medtronic pain pump also allows for full-body MRI scans when following the product labeling. Talk to your doctor or refer to product labeling for a full list of conditions. More than 300,000 patients worldwide have received therapy from Medtronic's drug infusion systems.

The Control WorkflowSM is an evidence-based approach, developed by clinicians for use with the Medtronic pain pump. It provides comprehensive guidance on oral opioid elimination with use of the Medtronic pain pump for appropriate patients. The oral opioid weaning considerations included in the Control WorkflowSM can be tailored to individual patients and assists physicians in identifying patients likely to have positive outcomes with the Medtronic pain pump. This evidence-based approach provides comprehensive guidance on therapy initiation, catheter placement, and dosing that could impact successful outcomes with the goal of sustained pain relief and functional improvement.^{3, 8, 10}

To learn more about the Medtronic Pain Pump, visit [Medtronic.com/PainPump](https://www.Medtronic.com/PainPump).

References

1. *Institute of Medicine. Relieving pain in America: a blueprint for transforming prevention, care, education, and research.* Washington DC, United States: The National Academies Press; 2011.
2. Gaskin DJ, Richard P. The economic costs of pain in the United States. *J Pain.* 2012;13(8):715-724.
3. Hamza M, Doleys D, Wells M, et al. Prospective study of 3-year follow-up of low-dose intrathecal opioids in the management of chronic nonmalignant pain. *Pain Med.* 2012;13(10): 1304-1313.
4. Smith TJ, Staats PS, Deer T, et al. Randomized clinical trial of an implantable drug delivery system compared with comprehensive medical management for refractory cancer pain: impact on pain, drug-related toxicity, and survival. *Journal of clinical oncology: official journal of the American Society of Clinical Oncology.* 2002;20(19):4040-4049.
5. Deer T, Chapple I, Classen A, et al. Intrathecal drug delivery for treatment of chronic low back pain: report from the National Outcomes Registry for Low Back Pain. *Pain Med.* 2004;5(1): 6-13.
6. Atli A, Theodore BR, Turk DC, Loeser JD. Intrathecal opioid therapy for chronic nonmalignant pain: a retrospective cohort study with 3-year follow-up. *Pain Med.* 2010;11(7):1010-1016.
7. Hatheway JA, Caraway D, David G, et al. Oral opioid elimination after implantation of an intrathecal drug delivery system significantly reduced health-care expenditures. *Neuromodulation: journal of the International Neuromodulation Society.* 2015;18(3):207-213.
8. Grider JS, Etscheidt MA, Harned ME, et al. Trialing and maintenance dosing using a low-dose intrathecal opioid method for chronic nonmalignant pain: a prospective 36-month study. *Neuromodulation: journal of the International Neuromodulation Society.* 2016;19(2):206-219.
9. Onofrio BM, Yaksh TL. Long-term pain relief produced by intrathecal morphine infusion in 53 patients. *J Neurosurg.* 1990;72(2):200-209.
10. Netter F. *Atlas of Human Anatomy.* 5th ed. Philadelphia, PA: Saunders Elsevier; 2010.



Under specific conditions for 1.5 T and 3.0 MRI scans. Requires interrogation to confirm pump status. Refer to product labeling.

Requires interrogation to confirm pump status.